Request for Influenza Molecular Diagnostic Performance Evaluation Panel
CDC’s Influenza Division is offering an Influenza Molecular Diagnostic Performance Evaluation Panel to qualified public health labs during the month of October 2020. This panel consists of nine specimens requiring identification of influenza type (A/B) and characterization of subtype and/or genotype to evaluate the performance of the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel kits for Influenza A/B typing (VER 2) (FluIVD03-9), Influenza A subtyping (VER 3) (FluIVD03-10), Influenza B Lineage Genotyping (VER 1.1) (FluIVD03-7), Influenza A/H5 subtyping (VER 4) (FluIVD03-11) and Influenza A/H7 (Eurasian Lineage) subtyping (FluEUA-01). The purpose of this exercise is to assist public health laboratories in evaluating performance of laboratories using molecular diagnostic methods for influenza detection and characterization, and to assist APHL and CDC in understanding performance of the CDC Flu rRT-PCR Dx Panel reagent kits in US public health laboratories. This exercise is not a CLIA or CAP certified proficiency testing program. Although participation in this exercise is encouraged, it is strictly voluntary.
Public health laboratories interested in participating in this performance evaluation exercise are requested to submit the enrollment from October 15th to November 5th, 2020.
If you have any questions, please direct them to FluPEP@cdc.gov.
Note: Beginning November 2nd , 2020, kits FR-1765 will be available to order through IRR ( www.internationalreagentresource.orgexternal icon ) (Catalog Number: PT0068, Lot Number: 20-0525).
All fields are required unless otherwise indicated.